Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Methyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL6038139 | 0.95 | — | — | |
| Water SCHEMBL1963160 | 0.84 | — | — | |
| Chloroform SCHEMBL27706310 | 0.78 | LMNA (0.50) | — | |
| Chloroform SCHEMBL28040546 | 0.78 | — | — | |
| Chloroform SCHEMBL8907442 | 0.78 | LMNA (0.50) | — | |
| Chloroform SCHEMBL9617984 | 0.78 | LMNA (0.50) | — | |
| Chloroform SCHEMBL25447 | 0.78 | — | — | |
| Chloroform SCHEMBL28063298 | 0.78 | LMNA (0.50) | — | |
| SCHEMBL295143 | 0.78 | — | — | |
| Isopropylamine SCHEMBL4947945 | 0.76 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | ASTRAEA THERAPEUTICS, LLC | 2024-02-22 | — | — | US | disclosed |
| US-RE49825-E1 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210053937-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2021-02-25 | — | — | US | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC | 2020-11-10 | — | — | US | disclosed |
| EP-0048614-B1 | 1-N-ACYLATED AND 1-N-ALKYLATED DERIVATIVES OF 4-0-SUBSTITUTED -2-DEOXYSTREPTAMINE AMINOGLYCOSIDES | ELI LILLY AND COMPANY (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0048613-B1 | 4-0-SUBSTITUTED -2-DEOXYSTREPTAMINE AMINOGLYCOSIDE DERIVATIVES, THEIR PREPARATION AND FORMULATIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1985-01-23 | — | — | EP | disclosed |
| US-4468512-A | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | disclosed |
| US-4468513-A | 2'-N-Acylated and 2'-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | disclosed |
| US-4424344-A | 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4424345-A | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| EP-0048614-A1 | 1-N-acylated and 1-N-alkylated derivatives of 4-0-substituted -2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | disclosed |
| EP-0048613-A1 | 4-0-Substituted -2-deoxystreptamine aminoglycoside derivatives, their preparation and formulations containing them | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | disclosed |
| US-4273855-A | Photographic diffusion transfer process and material for the production of color images and suitable compounds therefor | AGFA-GEVAERT N.V. (BE) | 1981-06-16 | — | — | US | disclosed |
| EP-0004400-A2 | Photographic diffusion transfer process and material for the production of colour images and suitable compounds therefor | AGFA-GEVAERT N.V. (BE) | 1979-10-03 | — | — | EP | disclosed |